{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:17:32Z","timestamp":1788445052648,"version":"build-2803163510"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Since the early 1990s, Ultraviolet (UV) A1 phototherapy has been described as an effective and safe treatment of a multitude of skin disorders. However, after 30\u2009years, its use has remained limited to few dermatological centers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To analyze the changes over the years and the current position of UVA1 phototherapy through a Real-World Evidence (RWE) study at a single tertiary referral center.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We reviewed the medical files of 740 patients treated between 1998 and 2022. Treatment results were collected, efficacy was assessed by a grading scale and acute adverse effects were registered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We treated patients with 26 different diseases. We registered marked improvement (MI) or complete remission (CR) in 42.8% of patients with morphea, 50% with Urticaria Pigmentosa, 40.7% with Granuloma annulare and 85.7% with skin sarcoidosis. Good results were obtained also in the treatment of chronic Graft Versus Host Disease (GVHD), Eosinophilic Fasciitis, Sclero-atrophic Lichen, skin manifestations of systemic lupus erythematosus and psoriasis of HIV+ patients. Systemic Sclerosis, Romberg\u2019s Syndrome, Bushke\u2019s Scleredema, Nephrogenic Fibrosing Dermopathy, REM Syndrome, Follicular Mucinosis, Pretibial Myxedema, Scleromyxedema, pemphigus foliaceus, chronic cutaneous lupus erythematosus, erythroderma of Netherton Syndrome and Necrobiosis Lipoidica were no or poorly responsive. In clinical indications where UVA1 was used as a second line phototherapy after narrow-band (NB)-UVB, we saw good MI or CR rates in Mycosis Fungoides (57% of patients), Atopic Dermatitis (33.9%), Pitiryasis Lichenoides chronica (50%), Pityriasis Lichenoides et varioliformis acute (75%) and Lymphomatod Papulosis (62.5%). Short-term adverse events were uncommon and mild.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Over the past decade, the annual number of treated patients has progressively declined for several reasons. Firstly, UVA1 phototherapy has taken a backseat to the cheaper and more practical NB-UVB phototherapy, which has proven effective for common indications. Secondly, the emergence of new, safe, and effective drugs for conditions such as atopic dermatitis, GVHD, and connective tissue disorders. Finally, our research has shown that UVA1 therapy is often ineffective or minimally effective for some rare diseases, contrary to previous case reports and small case series. Nonetheless, UVA1 continues to be a valuable treatment option for patients with specific skin disorders.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1295145","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:20:32Z","timestamp":1700752832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["The realistic positioning of UVA1 phototherapy after 25\u2009years of clinical experience and the availability of new biologics and small molecules: a retrospective clinical study"],"prefix":"10.3389","volume":"10","author":[{"given":"Piergiacomo","family":"Calzavara-Pinton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bettolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"ref1","first-page":"120","article-title":"High-dose-UVA1 phototherapy: a novel and highly effective approach for the treatment of acute exacerbation of atopic dermatitis","volume":"176","author":"Krutmann","year":"1992","journal-title":"Acta Derm Venereol Suppl"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0190-9622(92)70031-a","article-title":"High-dose UVA1 therapy in the treatment of patients with atopic dermatitis","volume":"26","author":"Krutmann","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-2230.2011.04256.x","article-title":"Ultraviolet A1 phototherapy: a British Photodermatology group workshop report","volume":"37","author":"Kerr","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/phpp.12185","article-title":"Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients","volume":"31","author":"Connolly","year":"2015","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1600-0781.2008.00328.x","article-title":"Efficacy of UVA1 phototherapy in 230 patients with various skin diseases","volume":"24","author":"Rombold","year":"2008","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/phpp.12833","article-title":"Efficacy of ultraviolet A1 phototherapy for inflammatory, sclerotic and neoplastic dermatological diseases: a 10-year tertiary referral center experience","volume":"39","author":"Ronen","year":"2023","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1600-0781.2010.00529.x","article-title":"Merkel cell carcinoma arising in immunosuppressed patients treated with high-dose ultraviolet A1 (320-400 nm) phototherapy: a report of two cases","volume":"26","author":"Calzavara-Pinton","year":"2010","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.3390\/jcm12093303","article-title":"Definition of the clinical characteristics of patients with moderate and severe atopic dermatitis for whom narrow-band UVB (NB-UVB) and medium-dose UVA1 phototherapies are still valuable treatment options at the age of biologics","volume":"12","author":"Rossi","year":"2023","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"121797","DOI":"10.1155\/2012\/121797","article-title":"Modern aspects of phototherapy for atopic dermatitis","volume":"2012","author":"Grundmann","year":"2012","journal-title":"J Allergy"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2340\/00015555754345","article-title":"Low dose versus medium dose UV-A1 treatment in severe atopic eczema","volume":"75","author":"Kowalzick","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/s0190-9622(98)70123-9","article-title":"High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial","volume":"38","author":"Krutmann","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1067\/mjd.2001.114743","article-title":"High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis","volume":"45","author":"Tzaneva","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/archderm.139.2.223","article-title":"Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis","volume":"139","author":"Legat","year":"2003","journal-title":"Arch Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2008.08.048","article-title":"Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis","volume":"60","author":"Majoie","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1365-2133.2008.08984.x","article-title":"Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study","volume":"160","author":"Gambichler","year":"2009","journal-title":"Br J Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1468-3083.2006.01531.x","article-title":"UVB therapy of pityriasis lichenoides--our experience with 29 patients","volume":"20","author":"Pavlotsky","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/09546630802449088","article-title":"Narrowband ultraviolet-B phototherapy in pityriasis lichenoides chronica","volume":"20","author":"Ersoy-Evans","year":"2009","journal-title":"J Dermatolog Treat"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40257-016-0216-2","article-title":"Phototherapy for Pityriasis Lichenoides in the pediatric population: a review of the published literature","volume":"17","author":"Maranda","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1039\/c8pp00170g","article-title":"Phototherapy of cutaneous T-cell lymphomas","volume":"17","author":"Trautinger","year":"2018","journal-title":"Photochem Photobiol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1067\/mjd.2002.122199","article-title":"Medium-dose ultraviolet A1 therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica","volume":"47","author":"Pinton","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jaad.2004.09.036","article-title":"Medium-dose UVA1 therapy of lymphomatoid papulosis","volume":"52","author":"Calzavara-Pinton","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/ced.12001","article-title":"Ultraviolet A1 phototherapy for mycosis fungoides","volume":"38","author":"Olek-Hrab","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000458149","article-title":"Ultraviolet A1 phototherapy in the treatment of early mycosis Fungoides","volume":"233","author":"Ad\u0131\u015fen","year":"2017","journal-title":"Dermatology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1067\/mjd.2001.110896","article-title":"\u201chigh-dose\u201d UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides","volume":"44","author":"Zane","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/phpp.12498","article-title":"The efficacy of UVA1 phototherapy in psoriasis: clinical and histological aspects","volume":"36","author":"Silpa-Archa","year":"2020","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/phpp.12581","article-title":"UVA1 phototherapy as a treatment option for plaque psoriasis in HIV-positive patients","volume":"36","author":"Arisi","year":"2020","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1562\/0031-8655(2001)074<0805:aohihs>2.0.co;2","article-title":"Activation of HIV in human skin by ultraviolet B radiation and its inhibition by NFkappaB blocking agents","volume":"74","author":"Breuer-McHam","year":"2001","journal-title":"Photochem Photobiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/00015550310015437","article-title":"UVA1 phototherapy of Netherton syndrome","volume":"84","author":"Capezzera","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1191\/0961203305lu2164cr","article-title":"Elimination of anticardiolipin antibodies and cessation of cognitive decline in a UV-A1-irradiated systemic lupus erythematosus patient","volume":"14","author":"McGrath","year":"2005","journal-title":"Lupus"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1177\/0961203317707064","article-title":"Ultraviolet-A1 irradiation therapy for systemic lupus erythematosus [published correction appears in lupus. 2017 Dec;26(14):1573]","volume":"26","author":"McGrath","year":"2017","journal-title":"Lupus"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2230.2005.02030.x","article-title":"A trial of low-dose UVA1 phototherapy for two patients with recalcitrant discoid lupus erythematosus","volume":"31","author":"Mitra","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s0140-6736(96)91600-1","article-title":"High-dose UVA1 for urticaria pigmentosa","volume":"347","author":"Stege","year":"1996","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1067\/s0190-9622(03)01483-x","article-title":"Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study","volume":"49","author":"Gobello","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/phpp.12248","article-title":"Narrow-band UVB phototherapy and psoralen-ultraviolet a photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients","volume":"32","author":"Brazzelli","year":"2016","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1600-0781.2005.00145.x","article-title":"UVA1 phototherapy for disseminated granuloma annulare","volume":"21","author":"Schnopp","year":"2005","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1600-0781.2010.00543.x","article-title":"Dramatic response of chronic ulcerating necrobiosis lipoidica to ultraviolet A1 phototherapy","volume":"26","author":"Radakovic","year":"2010","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2230.2005.02059.x","article-title":"UVA1 phototherapy for treatment of necrobiosis lipoidica","volume":"31","author":"Beattie","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jaad.2003.09.027","article-title":"Cutaneous sarcoidosis treated with medium-dose UVA1","volume":"50","author":"Mahnke","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1046\/j.1365-2133.2001.04356.x","article-title":"Successful ultraviolet A1 treatment of cutaneous sarcoidosis","volume":"145","author":"Graefe","year":"2001","journal-title":"Br J Dermatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1346-8138.2008.00417.x","article-title":"Ultrastructural changes induced in cutaneous collagen by ultraviolet-A1 and psoralen plus ultraviolet a therapy in systemic sclerosis","volume":"35","author":"Sakakibara","year":"2008","journal-title":"J Dermatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"CD005027","DOI":"10.1002\/14651858.CD005027.pub5","article-title":"Interventions for morphea","volume":"7","author":"Albuquerque","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/ced.13693","article-title":"Clinical, histological and high-frequency ultrasonographic evaluation (50 MHz) of morphea treated with ultraviolet A1 phototherapy","volume":"44","author":"Arisi","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2005.11.1063","article-title":"A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma","volume":"54","author":"Kreuter","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jaad.2008.12.013","article-title":"Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment","volume":"60","author":"Sator","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1067\/mjd.2002.118552","article-title":"Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study","volume":"46","author":"Kreuter","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/phpp.12478","article-title":"Acral bullous lichen sclerosus intolerant to UVA-1 successfully treated with narrowband ultraviolet B phototherapy","volume":"35","author":"Herz-Ruelas","year":"2019","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/ijd.16003","article-title":"UVA-1 phototherapy as adjuvant treatment for eosinophilic fasciitis: in\u2009vitro and in\u2009vivo functional characterization","volume":"61","author":"Tognetti","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s0190-9622(00)90023-9","article-title":"Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy","volume":"42","author":"Grundmann-Kollmann","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3389\/fmed.2018.00237","article-title":"Ultraviolet A1 phototherapy for Fibrosing conditions","volume":"5","author":"Gambichler","year":"2018","journal-title":"Front Med"},{"key":"ref50","first-page":"1169","article-title":"Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease","volume":"88","author":"Calzavara Pinton","year":"2003","journal-title":"Haematologica"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e15478","DOI":"10.1111\/dth.15478","article-title":"Utility of phototherapy in patients with systemic sclerosis: systematic review","volume":"35","author":"Mizio\u0142ek","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1600-0781.2007.00308.x","article-title":"Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: controlled study with half-side comparison analysis","volume":"23","author":"Durand","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.ad.2017.06.021","article-title":"Morphea in Childhood: an Update. Morfea en la infancia: actualizaci\u00f3n","volume":"109","author":"Aranegui","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1001\/archderm.140.11.1322","article-title":"UV-A1 phototherapy improves nephrogenic fibrosing dermopathy","volume":"140","author":"Kafi","year":"2004","journal-title":"Arch Dermatol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1600-0781.2004.00106.x","article-title":"UVA-1 as a treatment for scleredema","volume":"20","author":"Janiga","year":"2004","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/archderm.144.7.947","article-title":"Scleredema diabeticorum case series: successful treatment with UV-A1","volume":"144","author":"Kroft","year":"2008","journal-title":"Arch Dermatol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/j.1346-8138.2010.01014.x","article-title":"Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy","volume":"37","author":"Thumpimukvatana","year":"2010","journal-title":"J Dermatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-5945-4-17","article-title":"Fibromatosis of the hand associated with EMO syndrome: a case report","volume":"4","author":"Appelhans","year":"2004","journal-title":"BMC Dermatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000018440","article-title":"Treatment of idiopathic mucinosis follicularis with UVA1 cold light phototherapy","volume":"201","author":"von Kobyletzki","year":"2000","journal-title":"Dermatology"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e15773","DOI":"10.1111\/dth.15773","article-title":"Successful treatment of follicular mucinosis with low-dose UVA1 phototherapy","volume":"35","author":"Gil-Villalba","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/jdv.12247","article-title":"Reticular erythematous mucinosis in an atypical pattern distribution responds to UVA1 phototherapy","volume":"28","author":"Amherd-Hoekstra","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1001\/archderm.140.6.660","article-title":"Treatment of reticular erythematous mucinosis with UV-A1 radiation","volume":"140","author":"Meewes","year":"2004","journal-title":"Arch Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1295145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:20:37Z","timestamp":1700752837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1295145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":63,"alternative-id":["10.3389\/fmed.2023.1295145"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1295145","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"article-number":"1295145"}}